EUCTR2004-004572-36-HU进行中（未招募）不适用
A Multi-Center, Randomized, Phase 3 Study of Adjuvant Oncophage versus Observation in Patients with High Risk of Recurrence after Surgical Treatment of Renal Cell Carcinoma
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Pre Surgery Inclusion Criteria
- •1. Primary-intact resectable renal cell carcinoma, eligible for nephrectomy with curative intent.
- •2. Tumour size is 5cm or more OR macroscopic nodes OR renal vien thrombus OR vena cava thrombus by radiologic evaluation to meet definition of at least stage I disease.
- •3. Performance status (ECOG scale) is 1 or less and life expectancy of greater than 3 months.
- •4. Age 18 years or above.
- •5. If randomized to HSPPC-96 treatment arm, male or female patients of child bearing potiential must agree to use contraception during the Tomour Evaluation phase of the study and for one month after the last vaccination.
- •6. Signed written informed consent must be obtained and documented according to ICH-GCP, the local regulatory requirements and the rules followed at each institution.
- •Post-surgery Inclusion Criteria (must be completed within 5 weeks of surgery)
- •1. Confirmation of renal clear cell histology with > 25% clear cell features as per pathological report determination.
- •2. Tumour stage, determined using 2002 AJCC TNM staging, considered to be of high risk for recurrence must meet one of the following stage definitions:
- •- Stage I, high grade (Fuhrman grade 3 and 4)
- •- Stage II high grade (Fuhrman grade 3 and 4), OR
- •- Stage III, OR
- •- Stage IV non-metastatic
- •3. Availability of at least 4 doses of autologous HSPPC-96 (at least 4 injections) for clinical administration produced from the tumour sample provided.
- •4. Adequate haematopoietic function (granulocytes NLT 1 x 10 9/L; platelets NLT 100 x 10 9/L, haemoglobin > 10 g/L.
- •5. Adequate renal and hepatic function as per:
- •- Creatinine NMT 1.5 x upper limit of normal
- •- Alkaline phosphatase < 2 x upper limit of normal
- •- Total bilirubin NMT 2 x upper limit of normal
- •- AST and ALT NMT 2 x the upper limit of normal
- •6. Negative serology tests for HIV-1, HIV-2, HTLV-1, Hepatitis B and Hepatitis C.
- •7. Performance status (ECOG scale) is 1 or less and life expectancy of greater than three months.
- •8. Adequate cardiac function maximum of class II per NYHA.
- •9. Women of childbearing potential must have a negative urine or serum pregnancy test before randomization.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Pre-surgery exclusion criteria:
- •1. Multifocal tumour of the kidney or bilateral kidney tumours.
- •2. Prior surgery or chemo-, hormonal-, immuno- or radiotherapy for renal cell cancer.
- •3. History of primary or secondary immunodeficiency, or patients using immunosuppressive drugs, e.g. systemic corticosteroids, cyclosporin A or any autoimmune disorder.
- •4. Current malignancies of any type in other sites.
- •5. History or other malignancy within the last five years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin.
- •6. Embolization of the renal artery prior to nephrectomy.
- •7. Known distant metastases, including enlarged distant lymph nodes on radiologic evaluation, either confirmed as malignant via biopsy or will be assumed malignant if not assessed pathologically.
- •8. Active uncontrolled infection or other serious medical illnesses.
- •9. Previous splenectomy or intended splenectomy at the time of surgery.
- •10. Intended use of any other investigational product within four weeks prior to randomization and throughout the Tumour evaluation Phase of the Study.
- •Post Surgery Exclusion Criteria (must be completed within 5 weeks of surgery)
- •1. Clinical evidence of metastatic or residual renal cell carcinoma as documented on any of the following required scans:
- •- Abdominal CT scan (with oral and IV contrast)
- •- Pelvic CT scan (with oral and IV contrast)
- •- Chest CT scan (without contrast)
- •2. Splenectomy performed during nephrectomy.
- •3. Use of any other investigational product for four weeks prior to randomization and throughout the Tumour Evaluation Phase of the study.
研究者
相似试验
进行中（未招募）
不适用
A Multi-Center, Randomized, Phase 3 Study of Adjuvant Oncophage versus Observation in Patients with High Risk of Recurrence after Surgical Treatment of Renal Cell CarcinomaRenal cell carcinoma stage unspecifiedEUCTR2004-004572-36-ATAntigenics Inc600
已完成
不适用
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab BETHPER-064-08F. HOFFMANN-LA ROCHE LTD.,34
进行中（未招募）
不适用
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab - BETH (CIRG 011 (TRIO)/NSABP B-44-I)EUCTR2007-005182-35-SIF. Hoffmann-La Roche Ltd.3,500
进行中（未招募）
1 期
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab - BETH (CIRG 011 (TRIO)/NSABP B-44-I)EUCTR2007-005182-35-GBF. Hoffmann-La Roche Ltd.3,509
进行中（未招募）
不适用
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab - BETH (CIRG 011 (TRIO)/NSABP B-44-I)Resected node-positive or high risk node-negative, invasive HER2-positive breast cancer.MedDRA version: 9.1Level: HLGTClassification code 10006291Term: Breast neoplasms malignant and unspecified (incl nipple)EUCTR2007-005182-35-SEF. Hoffmann-La Roche Ltd.3,500